FDA authorizes intradermal monkeypox vaccine

This week, the Food and Drug Administration (FDA) issued an emergency use authorization  (EUA) for the JYNNEOS monkeypox vaccine to be administered intradermally in smaller doses. The EUA will make vaccine available to up-to-five times as many people as the current supply would serve with the vaccine being injected subcutaneously. The Centers for Disease Control and Prevention updated its guidance on monkeypox vaccination the same day. The National Coalition of STD Directors and a former deputy director of the FDA’s Office of Vaccines Research and Review expressed concerns about the vaccination strategy, according to an article in STAT News. In a separate article this week, the publication explained how monkeypox spreads. (FDA news release, 8/9/22)